Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study-Reference-Cited by-同舟云学术

Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study

Published:2012-06-02 Issue:9 Volume:53 Page:1743-1748
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Lozanski Gerard,Ruppert Amy S.,Heerema Nyla A.,Lozanski Arletta,Lucas David M.,Gordon Amber,Gribben John G.,Morrison Vicki A.,Rai Kanti M.,Marcucci Guido,Larson Richard A.,Byrd John C.

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2012.668683

Reference51 articles.

1. Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia

2. Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia

3. Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia

4. Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy

5. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Rare Germline ATM Variants Influence the Development of Chronic Lymphocytic Leukemia;Journal of Clinical Oncology;2023-02-10

2. Prognostic significance of ATM mutations in chronic lymphocytic leukemia: A meta-analysis;Leukemia Research;2021-12

3. Chronic Lymphocytic Leukemia;Abeloff's Clinical Oncology;2020

4. ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2);Blood Cancer Journal;2016-09

5. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib;Blood;2015-04-16